Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

3045 PWToday Stories

New diabetes treatment Fiasp (fast-acting insulin aspart), now available in the UK, improves control of diabetes at mealtimes

12 Apr 17

Today, a new, fast-acting mealtime insulin1,2 for adults living with type 1 or type 2 diabetes has been launched in the UK. Fiasp® (fast-acting insulin aspart) is an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes, after meals, compared with the rapid-acting insulin, NovoRapid® (insulin aspart)3. Fast-acting insulin aspart will be made available to the NHS at no additional cost versus conventional insulin aspart and may help patients tighten the control of their blood sugar levels after meals.

“Managing blood sugar levels around mealtimes can be challenging for those living with diabetes. Mealtime insulins are usually taken by patients before eating to effectively reduce the meal-associated rise in blood sugar”, explains Professor David Russell-Jones, primary investigator for onset 1, Consultant Physician at the Royal Surrey County Hospital, and Professor of Diabetes and Endocrinology at the University of Surrey. “Poor control of blood sugar levels over the long-term can lead to serious and costly long-term complications such as amputation and blindness. So the availability of this fast-acting insulin aspart—that more closely matches a healthy body’s physiological response versus existing treatments—is an incremental improvement in care and may give patients a more effective tool with which to manage their diabetes at mealtimes”.

Fast-acting insulin aspart is absorbed faster than insulin aspart, appearing twice as fast in the bloodstream after injection2,4 versus conventional insulin aspart, which leads to improved glycaemic control after meals1,5. Fast-acting insulin aspart significantly improves overall glycaemic control in patients with type 1 diabetes1 and had comparable overall glycaemic control in patients with type 2 diabetes5, versus insulin aspart. Mealtime glucose control (i.e. blood sugar levels after meals) was also significantly improved in patients with type 1 or type 2 diabetes at 1 hour after eating vs insulin aspart1,5. These outcomes were achieved without a significant difference in the overall rate of severe or confirmed hypoglycaemia compared with insulin aspart1,5.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.